MRX-7EAT
Phase 3Small molecule
MRX-7EAT is one of 33 small molecule programs targeting Bursitis. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Sprain
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Keflex
Eli LillyApproved
Zyloprim
Alnylam PharmaceuticalsApproved
Oruvail
WWyeth-Lederle Vaccines
Approved
Bextra
TThe Searle Company Limited Pakistan
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Indocin
LLife Extension Foundation Inc.
Approved
Vioxx
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tylenol
KKenvue Brands
Approved
Paracetamol
GSKApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bursitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRX-7EAT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMEDRx USA, Inc.